Research programme: selective estrogen receptor modulators - Eisai/Radius

Drug Profile

Research programme: selective estrogen receptor modulators - Eisai/Radius

Alternative Names: ER-306323; ER-308698; SERMs research programme - Eisai/Radius

Latest Information Update: 25 May 2010

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Eisai Co Ltd
  • Class Tetrahydronaphthalenes
  • Mechanism of Action Selective estrogen receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued CNS disorders; Menopausal syndrome; Postmenopausal osteoporosis

Most Recent Events

  • 30 Jan 2008 RAD 1901 has moved into clinical development for the treatment of hot flushes
  • 29 Jun 2006 Radius has licensed exclusive rights to SERMs worldwide, excluding Japan
  • 06 Sep 2004 Preclinical trials in CNS disorders in Japan (Intraperitoneal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top